CL2017003017A1 - Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer - Google Patents

Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer

Info

Publication number
CL2017003017A1
CL2017003017A1 CL2017003017A CL2017003017A CL2017003017A1 CL 2017003017 A1 CL2017003017 A1 CL 2017003017A1 CL 2017003017 A CL2017003017 A CL 2017003017A CL 2017003017 A CL2017003017 A CL 2017003017A CL 2017003017 A1 CL2017003017 A1 CL 2017003017A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
intratumoral injection
immune response
tumor development
cancer
Prior art date
Application number
CL2017003017A
Other languages
Spanish (es)
Inventor
Planells Claudia Julieta Robles
Guerrero Giselle Estefani Sanchez
Castillo Claudio Antonio Acuña
San Martin Marcelo Cortez
Silvia Beatriz Matiacevich
Original Assignee
Univ Santiago Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Santiago Chile filed Critical Univ Santiago Chile
Priority to CL2017003017A priority Critical patent/CL2017003017A1/en
Publication of CL2017003017A1 publication Critical patent/CL2017003017A1/en
Priority to PCT/CL2018/050115 priority patent/WO2019104449A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

<p>La presente invención se relaciona con el área farmacéutica, y especialmente, con una composición farmacéutica para inyección intratumoral que comprende nanopartículas de origen natural (quitosano) que se usan como vectores para la encapsulación de genes de proteínas que son capaces de controlar el desarrollo tumoral, crear respuesta inmune o ambos. En particular, la composición farmacéutica para inyección intratumoral comprende nanopartículas de quitosano que encapsula ADN de la proteína de fusión de Reovirus Aviar (REO), la que retrasa el crecimiento tumoral y eventualmente conduce a su eliminación vía generación de sincicios, y su uso en el tratamiento del cáncer por transfección in vivo. </p>The present invention relates to the pharmaceutical area, and especially, to a pharmaceutical composition for intratumoral injection comprising naturally occurring nanoparticles (chitosan) that are used as vectors for encapsulation of protein genes that are capable of controlling the tumor development, create immune response or both. In particular, the pharmaceutical composition for intratumoral injection comprises chitosan nanoparticles that encapsulates DNA from the Avian Reovirus fusion protein (REO), which slows tumor growth and eventually leads to its elimination via syncytial generation, and its use in the In vivo transfection cancer treatment. </p>

CL2017003017A 2017-11-28 2017-11-28 Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer CL2017003017A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2017003017A CL2017003017A1 (en) 2017-11-28 2017-11-28 Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer
PCT/CL2018/050115 WO2019104449A1 (en) 2017-11-28 2018-11-27 Composition for intratumoral injection comprising a dna vector encapsulated in chitosan nanoparticles and use thereof in cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2017003017A CL2017003017A1 (en) 2017-11-28 2017-11-28 Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CL2017003017A1 true CL2017003017A1 (en) 2018-05-04

Family

ID=63046540

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003017A CL2017003017A1 (en) 2017-11-28 2017-11-28 Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer

Country Status (2)

Country Link
CL (1) CL2017003017A1 (en)
WO (1) WO2019104449A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080983A1 (en) * 2001-04-05 2002-10-17 The Uab Research Foundation Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins
US20140350087A9 (en) * 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
WO2014089029A1 (en) * 2012-12-03 2014-06-12 Ohio State Innovation Foundation Activation of innate immunity by mirna for cancer and infection treatment

Also Published As

Publication number Publication date
WO2019104449A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
ECSP15025845A (en) ANTI-CEACAM5 ANTIBODIES AND USES OF THEM
CY1123355T1 (en) ANTIBODIES TO CD73 AND USES THEREOF
CY1123138T1 (en) CYTOTOXIC PROTEINS CONTAINING CELL-TARGETING BINDING REGIONS AND SHIGA TOXIN A SUBUNIT REGIONS FOR SELECTIVE KILL OF SPECIFIC CELL TYPES
CO2017001023A2 (en) Antibody-Carrier Compositions and Methods for Making and Using Them
PE20181365A1 (en) SUBCUTANEOUS FORMULATIONS OF ANTI-CD38 ANTIBODIES AND THEIR USES
CO2018004564A2 (en) Modified friedreich ataxia genes and vectors for gene therapy
EA201690868A1 (en) PERSONALIZED IMMUNOTHERAPY OF SEVERAL TYPES OF NEURAL TUMORS AND TUMORS OF THE BRAIN
CR20180174A (en) NEW PEPTIDES, COMBINATIONS OF PEPTIDES AND SUPPORTS FOR USE IN THE IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS TYPES OF CANCER
BR112017007765A2 (en) adenosine deaminase-2 (ada2) compositions, variants thereof and methods of using it
CR20180027A (en) NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN THE SAME THERAPY AGAINST OVARY EPITELIAL CANCER AND OTHER TYPES OF CANCER.
MX359449B (en) Anti-cd70 antibody drug conjugates.
CR20170419A (en) NEW PEPTIDES AND NEW COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCER CANCER AND OTHER TYPES OF CANCER.
EA202090751A2 (en) A NEW METHOD OF IMMUNOTHERAPY OF SEVERAL KINDS OF TUMOR BLOOD DISEASES SUCH AS Acute Myeloid Leukemia (AML)
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
CY1122968T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A DIAMINO-HETEROCYCLIC CARBOXAMIDE COMPOUND AS AN ACTIVE INGREDIENT
AR080313A1 (en) COMPOSITIONS OF RECOMBINANT CANINE MACHINE VIRUS (CDV) AND ITS USES
MX358782B (en) Expression of chimeric ksac protein and method of producing soluble proteins by high pressure.
MA37749A1 (en) Vaccines against bluetongue and African horse sickness virus
JO3565B1 (en) Angiopoietin-like 4 antibodies and methods of use
PH12019550275A1 (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
MX2018006226A (en) 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential.
EA201991702A1 (en) SELF-ASSEMBLY PROTEIN NANOPARTICLES INCAPSULATING IMMUNITIES MULATING NUCLEIC ACIDS
CL2017003017A1 (en) Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer
BR112017002206A2 (en) koc1-derived peptide and vaccine including the same